INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Wednesday. The brokerage currently has a $25.00 price objective on the stock. Zacks Investment Research’s price objective would suggest a potential upside of 14.42% from the stock’s previous close.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

Shares of INDIVIOR PLC SPON ADR EA REPR 5 (NASDAQ:INVVY) opened at 21.85 on Wednesday. INDIVIOR PLC SPON ADR EA REPR 5 has a one year low of $9.29 and a one year high of $23.30. The firm’s 50-day moving average price is $0.00 and its 200 day moving average price is $0.00.

5 Day Chart for NASDAQ:INVVY

Receive News & Stock Ratings for INDIVIOR PLC SPON ADR EA REPR 5 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC SPON ADR EA REPR 5 and related stocks with our FREE daily email newsletter.